3 completed, 2 terminated. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Terminated 2 |
Follow PF-06372865: new trials by email Literature Review of PF-06372865 trials Research Report on PF-06372865
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures CVL-865 - Seizures | Phase 2 | Terminated | AbbVie | 105 | 2020-12-08 | 2025-12-11 |
| A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures Placebo, CVL-865 - Seizures | Phase 2 | Completed | AbbVie | 154 | 2020-01-27 | 2025-05-30 |
| PF-06372865 in Subjects With Photosensitive Epilepsy PF-06372865, Placebo, Lorazepam - Reflex Epilepsy, Photosensitive | Phase 2 | Completed | Pfizer | 7 | 2015-12-16 | 2018-03-14 |
| POC Study in Partially Responsive Generalized Anxiety Disorder PF-06372865. - Generalized Anxiety Disorder | Phase 2 | Terminated | Pfizer | 90 | 2014-11-01 | 2017-01-09 |
| PF-06372865 In Subjects With Chronic Low Back Pain PF-06372865, Placebo, Naproxen - Chronic Low Back Pain | Phase 2 | Completed | Pfizer | 302 | 2014-10-01 | 2017-01-04 |
Epilepsies, Partial (2) · Seizures (2) · Epilepsy, Reflex (1) · Generalized Anxiety Disorder (1)
United States (5) · Australia (2) · Poland (2) · Serbia (2) · South Korea (2) · Spain (2) · Ukraine (2)
PMID 35965432, PMID 29721364, PMID 30877186
2019 (2)